GLP-1 Medications and Testosterone: What the Research Actually Shows

Here’s a finding that doesn’t make many headlines: men taking GLP-1 receptor agonists for weight loss may be getting an unexpected bonus in the hormone department. A 2025 review published in Urology synthesized 16 clinical studies and concluded that GLP-1 receptor agonists likely have a beneficial effect on male reproductive hormones and testosterone levels, particularly in men dealing with metabolic dysfunction. That’s a meaningful signal — but the story is more nuanced, and more interesting, than a simple headline suggests.

To understand why GLP-1 medications might move the needle on testosterone, you first need to understand why obesity tanks it in the first place. Visceral fat isn’t passive tissue. It’s metabolically active, producing aromatase — the enzyme that converts testosterone into estrogen — while simultaneously driving chronic inflammation that suppresses the hypothalamic-pituitary-gonadal (HPG) axis. The result is a well-documented condition called functional hypogonadism: low testosterone paired with inappropriately normal gonadotropin levels. A 2022 review in Frontiers in Endocrinology confirmed that central or visceral obesity and the consequent inflammatory state play the main role in this hormonal imbalance in men with type 2 diabetes, though insulin resistance, glycemic control, and sleep apnea are also contributing factors, not the diabetes itself. That distinction matters enormously for how we think about treatment.

This is where GLP-1 medications enter the picture — not as direct testosterone boosters, but as powerful metabolic reset tools. Semaglutide, liraglutide, and tirzepatide drive significant fat loss, reduce systemic inflammation, and improve insulin sensitivity. When visceral fat decreases, aromatase activity drops, estrogen conversion slows, and the HPG axis can begin functioning more normally. The testosterone improvements seen in clinical studies are likely downstream of this metabolic correction rather than any direct hormonal action of GLP-1 itself.

What the Clinical Evidence Actually Shows

A 2026 review in Sexual Medicine Reviews examining weight-loss medications and sexual health found that GLP-1 receptor agonists show promising results in men, improving erectile function, testosterone levels, and sperm parameters. The mechanisms proposed include reduced adipose-driven aromatization, lower systemic inflammation, and direct GLP-1 receptor signaling in testicular tissue — receptors that, according to the 2025 Urology review, are confirmed to be present in male reproductive organs.

But here’s where the science demands honesty: a well-designed 2020 study in The Journal of Clinical Endocrinology and Metabolism put GLP-1 itself under a controlled microscope in healthy lean men. Researchers at Imperial College administered an eight-hour intravenous GLP-1 infusion to 18 healthy men and measured LH pulses, FSH, and testosterone with precision. The result? Acute GLP-1 administration did not significantly affect reproductive hormone secretion in healthy men — testosterone AUC, LH pulses, and FSH were all statistically identical between the GLP-1 and placebo arms. GLP-1 did meaningfully reduce food intake, but the reproductive axis was unmoved.

What this tells us is critical: GLP-1 medications don’t appear to directly stimulate testosterone production in men who already have healthy hormonal function. The testosterone benefits documented in other studies are almost certainly weight-loss-mediated — and that’s actually good news. It means the benefits are real, reproducible, and tied to a mechanism (fat loss and metabolic improvement) that any man can pursue regardless of whether he’s taking a GLP-1 medication.

A 2024 narrative review in Therapeutic Advances in Urology reinforced this point comprehensively, examining lifestyle modifications, medical treatments, and bariatric surgery side by side. The conclusion: Weight loss achieved through lifestyle modifications consisting of dietary adjustments and regular exercise improves testosterone levels and sexual function in men, while evidence for weight loss medications remains insufficient and bariatric surgery shows improvements despite certain limitations.. Multiple randomized controlled trials within that review confirmed testosterone enhancement from lifestyle-driven weight loss alone. The method matters less than the metabolic outcome.

What This Means Whether You’re On a GLP-1 or Not

If you’re using semaglutide or tirzepatide, these findings suggest your hormonal profile may improve as a secondary benefit of the fat loss you’re achieving — particularly if you’re carrying significant visceral fat and have any degree of functional hypogonadism. This isn’t guaranteed, and it’s not a replacement for working with an endocrinologist if you have clinical testosterone deficiency. But for men in the obese or metabolically compromised range, the hormonal upside of meaningful fat loss is well-documented and meaningful.

If you’re not on a GLP-1 medication — and most men aren’t — the research is equally relevant and arguably more empowering. The same metabolic levers that GLP-1 drugs pull through pharmacology, you can pull through progressive resistance training, a protein-anchored dietary approach that creates a calorie deficit, improved sleep quality, and stress management. Resistance training in particular has a well-established direct effect on testosterone through androgen receptor upregulation and reduction of cortisol — mechanisms that operate independently of body weight. Visceral fat reduction through any means relieves the aromatase burden on your hormonal system.

The practical priorities are consistent across every approach: reduce visceral fat, control inflammation, get adequate sleep, lift heavy enough to provide a meaningful anabolic stimulus, and eat enough protein to preserve muscle during any fat-loss phase. For men on GLP-1 medications, this framework is especially important because the muscle-preservation challenge is real — rapid weight loss without resistance training can erode lean mass alongside fat, potentially complicating the testosterone picture rather than improving it.

On the fertility front, the 2025 Urology review noted preclinical evidence that GLP-1 receptor agonists enhance spermatogenesis and sperm function in obese rodent models, and limited clinical data suggest possible improvements in semen parameters. However, the authors are direct: larger prospective studies are needed before any confident clinical recommendations can be made. Men actively trying to conceive while on GLP-1 medications should have that conversation explicitly with their reproductive endocrinologist or urologist.

The Takeaway

The testosterone story around GLP-1 medications is real but indirect. These drugs don’t supercharge the HPG axis on their own — in healthy men, the data shows they don’t move reproductive hormones at all. What they do is drive the fat loss and metabolic improvement that allows a suppressed hormonal system to recover. That’s a meaningful benefit for men with obesity-related functional hypogonadism. And it’s a benefit that isn’t exclusive to any particular drug or method. Reduce visceral fat, control inflammation, train with intention, protect your sleep — and your hormonal environment will reflect it. GLP-1 medications can be a powerful tool for getting there. So can a barbell and a well-structured diet. The destination is the same.